Fennec Pharmaceuticals Inc. (TSE:FRX) Director Rostislav Christov Raykov Sells 2,431 Shares

Posted by on Sep 7th, 2024

Fennec Pharmaceuticals Inc. (TSE:FRX – Get Free Report) Director Rostislav Christov Raykov sold 2,431 shares of the firm’s stock in a transaction that occurred on Wednesday, September 4th. The shares were sold at an average price of C$7.45, for a total value of C$18,115.81.

Rostislav Christov Raykov also recently made the following trade(s):

  • On Monday, July 1st, Rostislav Christov Raykov sold 2,431 shares of Fennec Pharmaceuticals stock. The stock was sold at an average price of C$6.13, for a total value of C$14,902.03.

Fennec Pharmaceuticals Trading Down 1.4 %

Shares of FRX stock opened at C$7.14 on Friday. Fennec Pharmaceuticals Inc. has a fifty-two week low of C$7.00 and a fifty-two week high of C$15.43. The company has a quick ratio of 10.17, a current ratio of 8.02 and a debt-to-equity ratio of 1,040.68. The business has a fifty day simple moving average of C$8.19 and a 200-day simple moving average of C$10.64. The stock has a market cap of C$195.35 million, a P/E ratio of 79.33 and a beta of 0.26.

Fennec Pharmaceuticals (TSE:FRX – Get Free Report) last announced its earnings results on Tuesday, August 13th. The biopharmaceutical company reported C($0.27) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of C$0.08 by C($0.35). The business had revenue of C$9.94 million for the quarter, compared to analyst estimates of C$18.67 million. Fennec Pharmaceuticals had a negative return on equity of 1,005.59% and a net margin of 5.59%. On average, analysts forecast that Fennec Pharmaceuticals Inc. will post 0.6058577 earnings per share for the current fiscal year.

Fennec Pharmaceuticals Company Profile

(Get Free Report)

Fennec Pharmaceuticals Inc operates as a biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons.

Read More

Insider Buying and Selling by Quarter for Fennec Pharmaceuticals (TSE:FRX)

Receive News & Ratings for Fennec Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fennec Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.